SpotItEarly partners with HITLAB to accelerate commercialization of its dog-sniffing, AI-powered cancer detection test.
Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...
A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results